Introduction
============

The worldwide increase in patient complexity, more concern for quality and safety, and a shortage of resources are the challenging terms of the equation many physicians and respiratory therapists have to face nowadays \[[@B1]-[@B3]\]. Mechanical ventilation is one of the life-saving techniques used at the bedside that is also associated with complications, including ventilator-induced lung injury and ventilator-associated pneumonia \[[@B4],[@B5]\]. To decrease the duration of mechanical ventilation, there is evidence suggesting that the use of a written protocol is helpful \[[@B6]\]. Writing and reading protocols are time consuming, resulting in fluctuation in protocol implementation and compliance; instructions cannot be explicit enough, resulting in variable interpretation of the protocol; and they are specific to one organisation, making transfer to another institution difficult. To overcome these limiting factors, protocols have been computerised and there is convincing evidence showing that computerised protocols may help to manage and wean adult patients \[[@B7],[@B8]\] and children with severe lung diseases \[[@B9],[@B10]\].

A new computerised protocol with closed loop control of ventilation and oxygenation (IntelliVent^®^; Hamilton Medical AG, Bonaduz, Switzerland) has recently become available and has been investigated in adult patients \[[@B11]\]. The present study is a pilot prospective evaluation of this new closed loop computerised protocol in stable mechanically ventilated children during the weaning phase.

Materials and methods
=====================

The study - which was approved by the Sainte Justine Hospital ethical committee (Montreal, Canada) and by Health Canada and was registered on clinicaltrials.gov (NCT01095406) - was realised between January 2010 and January 2011 in the paediatric ICU of the Sainte Justine Hospital, Montreal, Canada. Signed informed consent was obtained from legal representatives as well as consent for publication of this manuscript and accompanying images.

Patients
--------

During the study period, all consecutive admitted critically ill children under mechanical ventilation for at least 12 hours, younger than 18 years old, having predicted body weight (PBW) ≥ 3 kg and body mass index \< 40 kg/m^2^were screened daily for the study 5 days a week (Monday to Friday). PBW was the weight at the 50th percentile for age and sex from the National Center of Health Statistics growth chart.

The study was in essence a pilot investigation and was designed primarily to evaluate the safety of the new computerised protocol. Children were therefore included if they fulfilled the following criteria: able to breathe spontaneously; ventilated with proximal airway plateau pressure ≤ 25 cmH~2~O, positive end-expiratory pressure (PEEP) ≤ 8 cmH~2~O, with fraction of inspired oxygen (FiO~2~) ≤ 60% to keep oxygen saturation from pulse oxymetry (SpO~2~) ≥ 95%, and arterial partial pressure of CO~2~\< 70 mmHg on the last arterial blood gas; endotracheal tube leakage \< 20% of the inspired tidal volume (VT), because the new computerised protocol requires correct information on VT; arterial partial pressure of CO~2~versus partial pressure in end-tidal CO~2~(PEtCO~2~) difference ≤ 7 mmHg; or not receiving muscle relaxant, vasopressor or inotropic medication (except dopamine \< 5 μg/kg/minute).

Children with a previous history of mechanical ventilation (more than 1 month) or tracheotomy, severe neuromuscular disease, cyanotic congenital heart disease and primary pulmonary hypertension were excluded, as well as brain-death children and children receiving palliative care.

An analysis was planned after the inclusion of five patients (run-in phase) because there was no clinical experience of this mode of ventilation. The analysis of the run-in phase showed that children with PBW \< 7 kg had an increase in minute ventilation (MV) because of technical reasons (high apparatus dead space with the S1 device due to the proximal flow sensor + mainstream CO~2~analyser in series). The investigators decided to only include children with PBW \> 7 kg. The four patients under 7 kg PBW and already included in the run-in phase were not analysed, although they went through the study without adverse effects (see Safety evaluation below).

Study design
------------

All included patients were prospectively enrolled in a sequential nonrandomised study during which they received five consecutive 60-minute periods of ventilation (Figure [1](#F1){ref-type="fig"}): pressure support ventilation (PSV) using the ventilator already connected to the patient (Servo-*i*; Maquet Gmbh & Co. KG, Rastatt, Germany) with the level of inspiratory pressure (P~insp~) set by the attending intensivist prior to the inclusion (PSV_before); adaptive support ventilation (ASV) using a functional S1 prototype ventilator (Hamilton Medical AG); ASV with the CO~2~controller activated (ASV-CO~2~); ASV with the CO~2~and the O~2~controller activated (ASV-CO~2~-O~2~); and PSV using the Servo-*i*ventilator at the initial level of support (PSV_after).

![**Study protocol**. Included patients were prospectively enrolled in a sequential study during which they received five consecutive 1-hour periods of ventilation. PSV, pressure support mode; ASV, adaptive support ventilation mode; ASV-CO~2~, ASV and CO~2~controller; ASV-CO~2~-O~2~, ASV-CO~2~and oxygen controller.](cc11343-1){#F1}

Throughout the ventilation period with the S1 device and for safety reasons, a trained physician remained at the bedside.

The PSV mode was given with the servo-*i*ventilator because the S1 device had only the new computerised protocol and ASV inside. The ventilation modes were not randomised as we had to ventilate the children in PSV before and at the end of the study, and randomising the modes would require changing the ventilator in a randomised order as well, which was not allowed for safety reasons.

Ventilatory modalities
----------------------

ASV is a ventilatory modality commonly used in adults \[[@B11],[@B12]\] where, for a given MV set by the user according to the clinical conditions and arterial blood gases, the ventilator automatically selects an optimal combination of respiratory rate (RR) and VT based on the breath-by-breath estimation of the expiratory time constant. The level of support (mandatory rate and P~insp~) is automatically adjusted on a breath-by-breath basis to keep the patient as close as possible to the optimal RR and VT. If the patient breathes spontaneously, this mode works as a volume target-pressure regulated mode with a user-set MV guarantee. If not, the ASV mode works as a pressure control mode with a prescribed MV. In ASV, the MV is the parameter that is controlled and set by the user. To further control the VT (and more specifically to reduce the VT) or to limit P~insp~, the user must decrease the MV and the maximum P~insp~allowed (pressure limitation). At the bench, in doing so it has been recently shown that ASV was able to generate lower VT and P~insp~compared with the ARDSnetwork recommendations \[[@B13]\]. However, in some clinical studies when the maximum allowed pressure is permissive (60 cmH~2~O), high VT has been reported with ASV \[[@B14]\]. In our study, MV in ASV was set to match the MV measured during PSV_before. PEEP and FiO~2~were set as during PSV_before. The pressure limitation was set to limit the P~insp~to 25 cmH~2~O.

ASV-CO~2~is an evolution of ASV where MV is not set by the user but is automatically adjusted to keep the patient within ranges of RR and PEtCO~2~, captured at the proximal airway using the S1 flow sensor (PN 279331, single-use flow sensor linear between -120 and 120 l/minute with ± 5% error of measure; Hamilton Medical AG) and a mainstream CO~2~analyser (Capnostat 5, mainstream sensor with accuracy ± 5% for PEtCO~2~between 41 and 70 mmHg, dead space 5 ml; Hamilton Medical AG). The target range of RR is defined by a lower limit based on the Otis concept of optimal RR to minimise the work of breathing \[[@B15]\], and an upper limit depending on the actual MV; the higher the MV, the higher the upper RR limit. P~insp~increases when the patient RR is above the upper RR limit; P~insp~decreases when the patient RR is below the lower RR limit. Filtered PEtCO~2~is present in the background to keep the patient below the upper PEtCO~2~acceptable value (Figure [2](#F2){ref-type="fig"}). Ventilation changes are made on a breath-by-breath basis.

![**Functional algorithm of the ventilation and oxygen controller**. **(A)**Ventilation controller. The partial pressure in end-tidal CO~2~(PEtCO~2~) values are given with the quality index and derived from the mainstream CO~2~sensor with proprietary algorithms as a surrogate of arterial partial pressure of CO~2~. PEtCO~2~min and PEtCO~2~max are adjustable by the user and depend on the patient\'s severity estimated by the level of inspiratory pressure; that is, the higher the inspiratory pressure and the more permissive the PEtCO~2~limits. As an example and by default for an inspiratory pressure of 10 cmH~2~O, PEtCO~2~min is 35 mmHg and PEtCO~2~max is 41 mmHg. **(B)**Oxygen controller. The oxygen saturation from pulse oxymetry (SpO~2~) limits (SpO~2~safety and SpO~2~min) are adjustable by the user and depending on the patient\'s severity estimated by the positive end-expiratory pressure (PEEP) level; that is, the higher the PEEP level and the more permissive the SpO~2~limits. As an example and by default for a PEEP level of 5 cmH~2~O, SpO~2~safety is 88%, SpO~2~min is 93% and SPO~2~max is 98%. The PEEPopt is defined according to a PEEP-fraction of inspired oxygen (FiO~2~) table and PEEPmax set by the user. The patient SpO~2~is provided with a quality index and is derived from the pulse oxymeter with proprietary algorithms for artefact and motion rejections. MV, minute ventilation; RR, respiratory rate.](cc11343-2){#F2}

ASV-CO~2~-O~2~includes the above-described ASV-CO~2~regulation plus an automatic adjustment of PEEP and FiO~2~based on SpO~2~monitoring included in the ventilator. SpO~2~is obtained from a finger probe using standard technology, plus proprietary filtering and quality assessment before entering the algorithm: when SpO~2~is below a user-adjustable value, FiO~2~or PEEP is increased (Figure [2](#F2){ref-type="fig"}). These ventilation changes are made on a breath-by-breath basis. The choice between FiO~2~and PEEP increase is based on the ARDSnetwork tables \[[@B16]\] with user inputs regarding maximal and minimal PEEP values. The FiO~2~controllers and the PEEP controller can be activated or deactivated independently. In the present study both controllers were activated, but according to local policies regarding PEEP settings the minimal PEEP and maximal PEEP were respectively set at 5 and 10 cmH~2~O.

The investigators remained at the bedside during the entire duration of the study and were allowed to switch back to manual adjustment of the settings. As for any mode of ventilation, the user has to set alarms for VT, for airway pressure as well as for monitoring parameters such as SpO~2~and PEtCO~2~.

Data collection
---------------

Patient characteristics including demographic data, diagnosis, severity scores, clinical data at inclusion and outcomes were collected from the charts. When connected to the S1 device, monitoring values (including SpO~2~, PEtCO~2~and mechanical ventilation monitoring), settings and alarms were recorded on a breath-by-breath basis using a dedicated data-logging system attached to the ventilator. Minute-to-minute data from the Servo-*i*were collected using a compact flash reader connected to the device.

Breath-by-breath data were analysed *ex vivo*to calculate the number of normal breaths as defined by 10 breaths/minute \< RR \< 40 breaths/minute, VT \> 5 ml/kg PBW and 25 mmHg \< PEtCO~2~\< 55 mmHg. The primary end point of the study was the percentage of time spent with normal ventilation, defined as the number of normal breaths out of the total number of breaths collected. During PSV_before and PSV_after, PEtCO~2~was dropped from the definition as it was not recorded with the Servo-*i*ventilator.

The number of ventilation setting changes was compared between the five consecutive 60-minute periods of ventilation. A ventilation setting change corresponded to a modification of PEEP or FiO~2~in any ventilation mode, a change of P~insp~in PSV or a change of minute volume in ASV, ASV-CO~2~or ASV-CO~2~-O~2~.

Safety evaluation
-----------------

Safety was evaluated by recording adverse events as defined by ISO 14155 standards (ISO 14971:2007, Medical devices \-- Application of risk management to medical devices) and by the number of switch back to PSV or to controlled ventilation by the intensivist present at the bedside, whatever the reason. The protocol was terminated and the child ventilated with the previous conventional ventilation if a sustained change was demonstrated in any of the following: decrease in SpO~2~\< 92% requiring increase in FIO~2~\> 60%; increase in PEtCO~2~above the value before connection with the S1 device, requiring an increase of positive P~insp~\> 25 cmH~2~O above PEEP; increase in heart rate \> 180 beats/minute for 15 minutes; increase in RR \> 60 breaths/minute for 15 minutes; or uncontrolled agitation.

Sample size
-----------

There were no previously existing data on the percentage of time spent with normal ventilation in children during mechanical ventilation. A similar study in adults observed that patients in PSV mode spent 66 ± 23% in the normal ventilation range compared with 93 ± 8% of patients ventilated with a closed loop computerised protocol \[[@B17]\]. From this study \[[@B17]\], we calculated that 16 patients would be required to find a statistical difference for such a difference with an α risk of 0.05 and a β risk of 0.9.

Statistical analysis
--------------------

As the parameters studied did not have a normal distribution, data are shown as the median with 25% and 75% interquartile ranges. Medians were compared using a Kruskal-Wallis one-way analysis of variance on ranks and paired tests when *P*\< 0.05 using Sigma Stats for Windows version 3.5 (Systat Software, Inc., Richmond, CA, US).

Results
=======

During the study period, 196 patients were screened and 15 patients with PBW \> 7 kg were included. These 15 patients were ventilated for a median of 55 hours before inclusion (Table [1](#T1){ref-type="table"}). One patient (Patient 12, Table [1](#T1){ref-type="table"}) did not undergo the ventilation periods with the S1 device due to the use of a neonatal flow sensor by mistake, which did not allow ventilating in the ASV mode, and was therefore excluded from analysis. The remaining 14 patients went through the study without side effects, without switching to PSV or controlled ventilation, or without early protocol termination when they were ventilated with the S1 ventilator.

###### 

Clinical description of the patients at inclusion

  Patient   Age (months)   PBW (kg)   PIM2 (%)   PELOD   Main diagnosis              Data at inclusion                         
  --------- -------------- ---------- ---------- ------- --------------------------- ------------------- ---- ----- ------ --- ----
  1         36             12         0          12      Rhabdomyosarcoma            21                  15   100   0.25   5   36
  2         195            57         0          2       Scoliosis-encephalopathy    26                  13   98    0.25   5   34
  3         93             27         3          2       Polytraumatism              240                 15   98    0.30   5   40
  4         28             14         2          3       Liver transplantation       72                  25   98    0.40   7   46
  5         59             17         0          1       Cranio-facial surgery       56                  17   98    0.25   5   47
  6         22             14         3          1       Laryngitis                  44                  15   96    0.35   5   38
  7         187            38         0          2       Congenital scoliosis        55                  21   99    0.25   5   39
  8         29             10         3          2       Septic shock                203                 26   95    0.40   5   48
  9         32             14         1          3       Encephalitis                46                  15   100   0.30   5   38
  10        54             16         0          1       Thyreoglosse cyst           31                  15   99    0.45   5   39
  11        9              7          3          1       Severe laryngitis           41                  18   98    0.35   5   41
  12        62             18         1          11      Pharyngeal abscess          38                  17   98    0.21   5   37
  13        45             15         13         1       Aspiration-encephalopathy   235                 11   98    0.30   5   59
  14        16             10         3          14      Encephalitis                66                  15   100   0.25   5   29
  15        165            49         2          12      Encephalopathy              75                  15   98    0.30   5   40
  Median    45             15         2          2                                   55                  15   98    0.30   5   39
  IQR25     29             13         0          1                                   40                  15   98    0.25   5   38
  IQR75     78             23         3          7                                   73                  18   99    0.35   5   43

PBW, body weight; PIM2, Paediatric Index of Mortality (percentage of risk of death) \[[@B29]\]; PELOD, Paediatric Logistic Organ Dysfunction score \[[@B30]\]; MV, mechanical ventilation; Ppeak, peak pressure at the proximal airway; SpO~2~, pulse oxygen saturation; FiO~2~, inspired oxygen fraction; PEEP, positive end-expiratory pressure; PaCO~2~, arterial partial pressure of CO~2~; IQR25 and IQR75, 25% and 75% interquartile range.

Compared with PSV_before (93% (79 to 95%)) and PSV_after (96% (83 to 100%)), ASV, ASV-CO~2~and ASV-CO~2~-O~2~kept the patients within normal ventilation for a similar percentage of time (respectively: 93% (80 to 95%), 94% (91 to 96%) and 94% (87 to 96%)) (Table [2](#T2){ref-type="table"}).

###### 

Time spent with normal ventilation, ventilation pattern, peak airway pressure, PEtCO~2~and SpO~2~

                                                  PSV_before         ASV                **ASV-CO**~**2**~   **ASV-CO**~**2**~**-O**~**2**~   PSV_after          *P*value
  ----------------------------------------------- ------------------ ------------------ ------------------- -------------------------------- ------------------ ------------
  Normal ventilation (% of the recording time)    93 (82 to 95)      94 (82 to 96)      95 (92 to 96)       95 (89 to 96)                    97 (85 to 100)     NS
  Number of ventilation setting changes/patient   0 (0 to 0)         0 (0 to 0)         78 (58 to 119)      81 (35 to 250)                   0 (0 to 0)         \< 0.001\*
  Respiratory rate (breaths/minute)               17 (14 to 21)      21 (18 to 24)      23 (19 to 25)       22 (18 to 27)                    20 (16 to 26)      NS
  Tidal volume (ml/kg)                            8.3 (7.1 to 9.3)   8.7 (7.7 to 9.7)   8.9 (8.2 to 9.7)    8.4 (7.8 to 9.7)                 7.9 (6.7 to 8.9)   NS
  Paw-peak (cmH~2~O)                              16 (15 to 18)      15 (14 to 22)      16 (14 to 19)       17 (15 to 21)                    15 (14 to 19)      NS
  PEtCO~2~(mmHg)                                  \-                 43 (39 to 45)      43 (40 to 45)       43 (39 to 47)                    \-                 NS
  SpO~2~(%)                                       \-                 98 (95 to 100)     99 (96 to 100)      98 (95 to 100)                   \-                 NS

Results of time spent with normal ventilation, ventilation pattern, peak airway pressure, partial pressure of end-tidal CO~2~(PEtCO~2~) and pulse oxygen saturation (SpO~2~) during the five 1-hour periods investigated. Results given as the median with 25% to 75% interquartile range. Normal ventilation is the percentage of time with normal breath as defined by 10 breaths/minute \< respiratory rate \< 40 breaths/minute, tidal volume \> 5 ml/kg predicted body weight and 25 mmHg \< PEtCO~2~\< 55 mmHg. PSV, pressure support ventilation; ASV, adaptive support ventilation, ASV-CO~2~, ASV plus the CO~2~controller; ASV-CO~2~-O~2~, ASV-CO~2~plus the oxygen controller; Paw-peak, peak proximal airway pressure; NS, *P*\> 0.05. \**P*\< 0.001 for ASV versus ASV-CO~2~and for ASV versus ASV-CO~2~-O~2~.

The VT, RR, peak inspiratory airway pressure (Paw-peak) and MV were equivalent with all modalities. PEtCO~2~and SpO~2~were also equivalent between ASV, ASV-CO~2~and ASV-CO~2~-O~2~(Table [2](#T2){ref-type="table"}). The standard deviation to estimate the variability of Paw-peak was much higher with ASV, ASV-CO~2~and ASV-CO~2~-O~2~as compared with PSV (Figure [3](#F3){ref-type="fig"}). As compared with ASV, there were significantly more ventilator setting adjustments (automatic) in ASV-CO~2~and ASV-CO~2~-O~2~(77 (57 to 120) per patient and 80 (32 to 272) per patient, respectively) (Table [2](#T2){ref-type="table"}).

![**Peak airway pressure of children during the 1-hour periods of mechanical ventilation**. Peak inspiratory airway pressure (Paw-peak; median and standard deviation (SD)) of the 14 children included during the five 1-hour periods of mechanical ventilation. The median values were not statistically different, but the SDs of individual breath-by-breath values (right panel) were significantly higher, suggesting more variability in adaptive support ventilation (ASV), ASV and CO~2~controller (ASV-CO~2~) and ASV-CO~2~and oxygen controller (ASV-CO~2~-O~2~) as compared with pressure support ventilation (PSV).](cc11343-3){#F3}

In four patients, during the 60-minute period with ASV-CO~2~-O~2~, an automatic increase of PEEP from 5 cmH~2~O to 7 to 9 cmH~2~O was observed due to a transient decrease in SpO~2~. The physician manually returned the PEEP to 5 cmH~2~O because it was not in his practice to increase PEEP in this situation.

The median total duration on the ventilator was 97 hours (55 to 207 hours) and the length of stay in the ICU was 5 days (4 to 13 days). At 28 days after the inclusion, all patients were alive, none was on mechanical ventilation and five patients remained in the hospital.

Discussion
==========

ASV alone or combined with the automatic adjustment of minute volume was safe and provided a similar breath pattern as compared with PSV. This was achieved, however, with more ventilator automatic adjustments and more variability in Paw-peak as compared with ASV and PSV. The apparatus dead space with the S1 device due to the proximal flow sensor + mainstream CO~2~analyser in series restrained the ventilation to children with body weight \> 7 kg. As the patients were in a stable situation and not hypoxemic, little information was obtained regarding the oxygenation controller. In four patients, however, an automatic increase in PEEP was observed that was not considered usual practice by the physician in charge.

The present pilot study has several limitations that need to be addressed before raising some conclusions. First, comparing ASV, ASV-CO~2~and ASV-CO~2~-O~2~from the S1 device with PSV given with another ventilator is arguable. Even if the aim of the study was not to compare the performance of each mode in supporting the patient, this may indeed impact on the primary endpoint - that is, the time spent with normal ventilation, which was defined based on the RR, VT and PEtCO~2~. Furthermore, the data were acquired differently with the S1 device (breath by breath) as compared with the Maquet ventilator (minute by minute, equivalent to a filtering). PEtCO~2~was also not part of the definition of normal breathing in PSV, and PEtCO~2~is known to show high fluctuation on both sides in spontaneously breathing patients \[[@B18]\]. Whether minute-by-minute filtering and not having PEtCO~2~in PSV are overestimating the time in normal ventilation during PSV is questionable. As the S1 ventilator did not have the PSV mode, however, the study had to be carried out with the methodology described above.

Second, the different modes of ventilation were given sequentially and without randomisation. The total duration of the study was 5 hours and very obviously the patient\'s conditions may change over such a long period. However, the patient\'s respiratory conditions in PSV_after as compared with PSV_before were not different (Table [2](#T2){ref-type="table"}).

Third, the study was finally underpowered (14 patients analysed as compared with the 16 patients required by the power calculation). This was because of four patients weighing \< 7 kg and not being analysed. In one patient the new computerised protocol was also unable to work because of the wrong flow sensor (neonatal flow sensor) being on the device. However, an increased number of patients would probably not achieve statistical significance as the observed time spent in normal ventilation during PSV mode was higher than expected (93% instead of 66% as expected from a previous adult study \[[@B17]\]).

Fourth, the different modes were investigated over a short period of time (60 minutes) and in a very specific subpopulation of stable patients during the weaning phase. It is indeed impossible to estimate the safety of such a closed loop computerised protocol in more critically ill patients. The clinical impact of such a mode of ventilation is also not addressed by the present study. These studies will be the next steps.

Finally, the PEEP controller - which is probably the most critical in terms of safety - was set to very conservative working conditions (minimal PEEP 5 cmH~2~O and maximal PEEP 10 cmH~2~O). In four patients an increase of PEEP from 5 cmH~2~O to 7 to 9 cmH~2~O was observed due to a transient decrease in SpO~2~. The physician manually returned the PEEP to 5 cmH~2~O because it was not in his practice to increase PEEP in this situation. The present study is therefore not able to raise any conclusions regarding the PEEP closed loop computerised protocol, and further data are needed on the optimal PEEP during the weaning phase.

The present pilot study is therefore exploratory and can only indicate that in this stable population, over a short period of time (60 minutes) and within the experimental conditions (PEEP limited and manually controlled), ASV-CO~2~and ASV-CO~2~-O~2~were safe. Additional studies are definitely required before raising any conclusion on safety or effectiveness during longer period of ventilation and in patients with more critical conditions.

Interesting observations can be raised, however, from the present study. First, in babies with body weight \< 7 kg, the apparatus dead space (proximal flow sensor in series with the PEtCO~2~sensor) was relatively high, inducing an increase in MV as compared with PSV. As already shown in adult patients, the dead-space-related increase in MV and subsequent changes in the patient\'s optimal RR and VT combination is hardly predictable \[[@B19]\]. As most of the children admitted to the paediatric ICU weigh \< 7 kg \[[@B20]\], it is critical to reduce the apparatus dead space as much as possible before using such a computerised protocol.

Second, more ventilator automatic adjustments and more variability in Paw-peak were observed in ASV-CO~2~and ASV-CO~2~-O~2~as compared with ASV and PSV with ultimately equivalent PEtCO~2~. This is most probably due to the patients\' subclinical changing conditions that are taken into account by ASV-CO~2~and not with ASV or PSV. More variable ventilation may have an impact on lung recruitment, as suggested in atelectatic animal models \[[@B21],[@B22]\], and may have an impact on patient comfort, as suggested by studies on variable modes using pressure support \[[@B23],[@B24]\].

Third, although designed for children and adult patients, and already on the market for 10 years, publications are lacking on ASV in children. In the very first publication from Laubscher and coworkers in 1994 \[[@B25]\], some paediatric patients were included but ASV was applied only for a couple of minutes to test the start-up procedure in selecting the VT and RR. To our best knowledge, ASV has never been compared with PSV in the paediatric population. Bearing in mind the abovementioned limitations and publications from adult populations reporting higher VT with ASV when the pressure limitation is high \[[@B14]\], it is worth noting that breath patterns with both modes were not drastically different. Once again, this would deserve additional investigation.

Finally, although not really challenged by the population enrolled in the study, an automatic control of FiO~2~based on SpO~2~has been already investigated in neonates \[[@B26],[@B27]\] and in adults \[[@B28]\], with increased time spent with adequate SpO~2~when compared with usual care. The present study is in line with these previously published results.

Conclusion
==========

The present pilot prospective study shows the feasibility of using a closed loop computerised protocol on ventilation and oxygenation over a short time period in stable, spontaneously breathing paediatric patients starting the weaning process. Over the study period, children with body weight \> 7 kg were kept with normal ventilation most of the time and no safety issues were reported. Future studies should be designed to address safety and effectiveness of such a closed loop computerised protocol as compared with conventional ventilation in children with more challenging respiratory conditions and over a longer period of time.

Key messages
============

• A closed loop computerised protocol seems feasible in paediatric ventilated patients during the weaning phase.

• Compared with PSV, the closed loop computerised protocol may keep patients within normal ventilation for a similar percentage of time.

• Compared with PSV, the closed loop computerised protocol seems to generate more airway pressure variability.

• Compared with PSV, the closed loop computerised protocol may adjust the ventilator more often.
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